Back to Search
Start Over
Cytotoxicity of the CD3 × CD20–bispecific antibody epcoritamab in CLL is increased by concurrent BTK or Bcl-2 targeting
- Source :
- Blood Advances; 20230101, Issue: Preprints
- Publication Year :
- 2023
-
Abstract
- •Epcoritamab-mediated killing of CLL cells by autologous T cells correlates with the effector-to-target ratio but not CD20 expression.•Epcoritamab efficacy is increased by concurrent use of a BTKi or venetoclax, supporting combination therapy.
Details
- Language :
- English
- ISSN :
- 24739529 and 24739537
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Blood Advances
- Publication Type :
- Periodical
- Accession number :
- ejs63146176
- Full Text :
- https://doi.org/10.1182/bloodadvances.2022009517